KOE · 216080.KQ
JETEMA, Co., Ltd.
₩5,810-₩110 (-1.86%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.49% below the high.
Loading market information…
KOE · 115450.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 04:35 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.18% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow HLB Therapeutics Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩5,810-₩110 (-1.86%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.49% below the high.
₩5,260-₩90 (-1.68%)
EASY BIO,Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.55% below the high.
₩3,720+₩100 (+2.76%)
Helixmith Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 62.65% below the high.
₩13,470-₩610 (-4.33%)
Anterogen.Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 78.2% below the high.
₩10,850-₩100 (-0.91%)
Macrogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.09% below the high.
₩2,985+₩15 (+0.51%)
MedPacto, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.49% below the high.
₩2,165₩0 (0.0%)
Genexine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.09% below the high.
₩920+₩14 (+1.55%)
Amicogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.65% below the high.
